Drug Delivery Systems Market Size, Share & Industry Analysis, By Type (Inhalation, Transdermal, Injectable, and Others), By Device Type (Conventional and Advanced), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others), and Regional Forecast, 2024-2032

The global drug delivery systems market size was valued at USD 42.71 billion in 2023 and is projected to grow from USD 46.23 billion in 2024 to USD 96.34 billion by 2032, exhibiting a CAGR of 9.6% during the forecast period (2024-2032). A drug delivery system is a device that enables the introduction of a drug in the body and improves its efficacy and safety by controlling its rate, time, and place of release. The systems include auto-injectors, jet-injectors, and syringes. The manufacturers of drug delivery systems either distribute their products to pharmaceutical companies or consumers through various pharmacies, such as retail pharmacies, hospital pharmacies, and online pharmacies.

The large-scale vaccination drives to minimize the spread of COVID-19 fueled the demand for drug delivery systems, which will continue to increase during the forecast period as well. Moreover, factors, such as the surging number of chronic diseases, growing awareness & adoption of advanced delivery systems for drug administration, and emerging novel technologies are driving the market. Furthermore, the market players focusing on various strategies, such as new product launches and collaborations are expected to contribute to the drug delivery market growth in the coming years.

• For instance, in October 2021, Nemera launched an ENT drug delivery device, UniSpray, to broaden its product portfolio. Such a product launch is expected to increase the market revenue during the forecast period.

The COVID-19 pandemic slowed down the market in 2020 due to factors, such as reduced hospital admissions, disruption in supply chain, temporary halt in manufacturing, and others across the globe. However, with the launch of COVID-19 vaccines and mass vaccination drives, there was a significant acceleration in manufacturers’ production of injectable drug delivery systems to meet the global medical needs.

• For instance, according to the World Health Organization (WHO), more than 10 billion doses of COVID-19 vaccines were given to the global population as of 7^th February 2022, resulting in an increase in the production capacity of the systems.

Moreover, decrease in patient visits to hospitals and clinics during COVID-19 increased the demand for safe and easy-to-use homecare solutions, which can be achieved using self-injection devices. The market players also developed advanced drug delivery devices that can be easily self-administered at home. The market in the post-pandemic period is expected to grow significantly due to increased hospital visits and the launch of advanced drug delivery systems, among others.

Drug Delivery Systems Market Trends

Strategic Collaborations and New Product Launches to Boost Market Growth

The companies operating in the market constantly focus on strategies, such as collaborations and development & introduction of new products. These strategies will help the companies increase their revenue, thereby propelling the market growth.

The advent of new products with increased safety and user-friendly features is expected to fuel the pharmaceutical industry’s growth. Additionally, better dosing features also complement drug treatment outcomes and increase the potential of disease management in homecare settings.

• For instance, in November 2021, Ypsomed launched YpsoMate, the world’s first auto-injector for prefilled syringes with integrated connectivity.

Moreover, rise in collaborations between market players and pharmaceutical companies to develop and launch products will further boost the market growth. For instance, in April 2021, KINDEVA DRUG DELIVERY collaborated with Cambridge Healthcare Innovations Limited (CHI) to develop and commercialize CHI’s αeolus Dry Powder Inhaler (DPI) platform technology.

Drug Delivery Systems Market Growth Factors

Increase in Shift of Patients Toward Advanced Drug Delivery Systems to Favor Market Growth

The rise in patients’ preference toward advanced drug delivery systems is due to their decreased variability in systemic drug concentrations and ability to deliver a drug more selectively to a specific site with greater accuracy. These features have led to an increased adoption of self-administered devices among patients.

• For instance, in May 2021, Gerresheimer AG, in collaboration with SensAir, presented an on-body drug delivery platform which can deliver high viscosity drugs, such as biologics. The SensAir on-body drug delivery device is said to be easy to use and allows patients to start medications at home.

Moreover, the digitalization of medical devices has increased the awareness of advanced products among patients. Digitalization of these products provides various advantages, such as needle-free injection, controlled dosage, and higher flexibility of self-administration, leading to an increase in the adoption of these devices.

• In December 2022, Biocorp received the U.S. FDA approval for its smart sensor, Mallya, which connects directly to insulin pen injectors to transform them into a connected device. The sensor automatically collects the data and transmits it to the dedicated application.

Furthermore, the shift of patient focus toward an advanced drug delivery system has increased in recent years due to its efficiency and reduced side effects. Also, several drug delivery systems have been developed using advanced systems for more convenient, controlled, and targeted delivery.

• For instance, as per the data published by Heliyon in June 2023, modern drug delivery systems are formulated using advanced technology to expedite targeted delivery of medication, optimizing its effectiveness while minimizing off-target accumulation in the body. As a result, this system plays an important role in disease management and treatment.

Thus, the patients’ shift toward advanced products, combined with increased government initiatives to raise public awareness of these products, are expected to boost the drug delivery systems market growth in the coming years.

Increasing Burden of Chronic Diseases to Drive Market Growth

In recent years, chronic diseases, such as asthma, Chronic Obstructive Pulmonary Disease (COPD), cancer, diabetes, and other diseases have been the leading causes of death globally. Factors, such as the growing prevalence of these chronic diseases and emerging technologies for treating them are expected to fuel the market progress during the forecast period. According to the United Health Foundation, in 2022, about 56 million adults (16.9% of the total population) in the U.S. were aged 65 years and above. Such a large group of the geriatric population is susceptible to chronic diseases, which is expected to increase the adoption of such systems.

Moreover, in the past years, targeted drugs have improved the management of several chronic diseases. An optimal drug delivery system has the potential to enhance the therapeutic benefits of targeted drugs and reduce systemic adverse effects, providing advantages for patients with chronic diseases.

Furthermore, increase in product launches and digitalization in the healthcare sector have generated massive growth opportunities for the market players.

RESTRAINING FACTORS

Product Recalls and Stringent Regulations to Hinder Market Growth

The major factors restraining the market growth are strict regulations and guidelines associated with the approval of drug delivery devices and product recalls by the U.S. FDA. According to an article published by Drugwatch in 2021, on average, about 4,500 drugs and devices are recalled from the U.S. shelves each year.

The product recalls are mainly due to adverse effects, non-compliance with standards, and data security issues, thereby limiting the growth of the market.

• For instance, in October 2022, Roche recalled its new eye drug delivery device, Susvimo, from the market. The problem is related to the septum or the seal on the port delivery device that keeps the medication from leaking out once it’s been injected. As the product did not meet the company’s performance standards, it decided to stop the port delivery system distribution.


• Similarly, in June 2021, Smiths Medical initiated class I recall for Jelco Hypodermic Needle-Pro Fixed Needle Insulin Syringe owing to incorrect graduated markings. Such manufacturing defects can cause overdose or under dose of insulin, leading to serious problems among patients.

The technologically advanced products go through various regulatory approval processes. The stringent regulations of the regulatory bodies to evaluate the performance and safety of the products are expected to limit the launch of innovative products during the forecast period.

The invasive nature of the products could impact the trust of the customer in the device, and strict regulations to approve the products are limiting the growth of the market.

Drug Delivery Systems Market Segmentation Analysis

By Type Analysis

Rising Demand for Syringes to Fuel Adoption of Injectable Drug Delivery Systems

Based on type, the market is segmented into inhalation, transdermal, injectable, and others.

The injectable segment held the highest market share in 2023 and is projected to record the highest growth rate during the forecast timeframe. The rising demand for wearable injectable systems for drug delivery is expected to increase product launches, thereby spurring the segment’s growth. Moreover, the increasing number of vaccination drives across the world is boosting the demand for syringes, which is expected to contribute to the segment’s growth in the future.

• For instance, in 2021, Becton, Dickinson, and Company (BD) announced that it had received orders for needles and syringes, totaling 2 billion injection devices to support the global COVID-19 vaccination efforts. Such a high requirement of syringes and needles is expected to boost the segment’s growth.

The inhalation segment is predicted to register a substantial CAGR during the forecast period of 2024-2032. The growth of the inhalation segment is attributed to the rising adoption of inhalers to tackle the increasing prevalence of respiratory disorders, such as asthma and other bronchial conditions. Moreover, growth in the product launches of inhalation systems in the market by the key players is expected to fuel the market growth during the forecast period. Also, several market players are partnering with contract development and manufacturing organizations for the modification of existing drug delivery systems.

• For instance, in December 2023, Kindeva Drug Delivery and Orbia Fluorinated Solutions (Koura) announced the co-development collaboration for the conversion from existing marketed pressurized Metered Dose Inhaler (pMDI) products to Koura’s more sustainable and environmentally-conscious medical propellant.

By Device Type Analysis

Rising Demand for Biosimilar Products to Trigger Adoption of Conventional Drug Delivery Systems

Based on device type, the market is segmented into conventional and advanced.

The conventional segment held the largest market share in 2023 and is projected to record a substantial CAGR during the forecast timeframe. The segment’s considerable expansion is due to the growing demand for biosimilar products and low cost of devices. Furthermore, the rising prevalence of chronic diseases, such as asthma, diabetes, and cardiovascular diseases (CVD) is expected to increase the demand for conventional systems, especially in developing countries that are more dependent on conventional systems than advanced systems.

• For instance, according to a study published by the NCBI in June 2021, the prevalence of at least one chronic disease was more than 43% in the Southeast region of Brazil, which is expected to fuel the adoption of conventional systems during the forecast period.

The advanced segment is expected to register the highest CAGR during the forecast period. The high preference for and continuously increasing adoption of advanced products is due to their advantages, such as high therapeutic effectiveness, better patient compliance, and reduced treatment cost. Furthermore, rising geriatric population, technological advancements, and increasing demand for novel products in the market are the key factors driving the growth of the segment.

By Distribution Channel Analysis

Surge in Hospital Admissions to Drive Product Sales across Hospital Pharmacies

On the basis of distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and others.

The hospital pharmacies segment is expected to dominate the global market during the forecast period due to a large number of patient visits in hospitals. Hospital pharmacies are an integral unit of hospitals. Thus, an increase in patient visits to these medical centers will increase the distribution of drug delivery devices from hospital pharmacies. The rising number of hospitals in various countries is also expected to increase the distribution of these systems from hospital pharmacies, thereby spurring the segment’s growth.

The retail pharmacies segment is anticipated to account for a substantial market share during the forecast period. The segment’s growth is attributed to an increase in the number of retail pharmacies and rising investments by governments and other organizations. For instance, in February 2021, Clicks opened its 600th in-store pharmacy in South Africa. Such new retail pharmacies are expected to increase the distribution of these systems in the coming years.

The instant spike in demand for these systems from the others segment, which includes e-pharmacies and homecare pharmacies, is attributed to the rise in the awareness of these types of pharmacies that provide people with limited mobility better access to low-cost products.

REGIONAL INSIGHTS

On the basis of region, the global market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

The market in North America was valued at USD 17.33 billion in 2023 and will dominate the global drug delivery systems market share during the forecast period. Some of the contributing factors include rapid increase in the COVID-19 vaccination drives by the U.S. government, which boosted the demand for syringes. Furthermore, strong demand for these systems due to the increased number of hospital admissions in the region is expected to drive the market growth in North America during the forecast period.

• For instance, according to an article published by CIHI in April 2021, there were over 3 million acute inpatient hospitalizations in Canada in 2019–2020. These hospitalizations are expected to increase the demand for these systems in the region.

Rise in demand for advanced drug delivery systems, such as sensor-embedded devices and metered-dose inhalers, and growing incidence of chronic diseases are likely to drive the market growth in the region.

Europe held the second-largest market share in 2023 and is projected to register a significant CAGR during the forecast period. The growth is due to the rising awareness regarding advanced drug delivery devices and increasing adoption of advanced products in the region. Moreover, clinical trials to get key regulatory approvals for new products and introduction of new products by key players are expected to propel the market growth in the region.

• For instance, in September 2023, Medtronic received the CE mark approval for its new Simplera continuous glucose monitor (CGM). This device seamlessly integrates with the InPen smart insulin pen for real-time, personalized dosing guidance to simplify diabetes management.


• Similarly, in April 2021, Medtronic introduced its extended infusion set, an insulin delivery device, in select European countries, which can be worn for up to seven days.

The Asia Pacific market is expected to record the highest CAGR during the forecast period of 2024-2032. Some of the critical factors contributing to the market growth across the region include a large patient population, growing prevalence of chronic diseases, increasing healthcare expenditure in countries, such as China and India, and rising COVID-19 vaccination drives by these countries. Furthermore, manufacturers in India are increasing their production capacities to meet the rising demands of syringes, thereby fostering the overall market growth across the region.

Latin America held a substantial market share in 2023 and is projected to register a moderate CAGR during the forecast period. The region is experiencing an increase in healthcare expenditure to enhance the overall healthcare system, which is expected to improve the current services provided in healthcare facilities. This will result in rise in demand for drug delivery devices. The market growth in the Middle East and Africa is attributed to a worrying increase in the prevalence of chronic diseases in the region, surge in hospital admissions, and increasing burden of asthma and diabetes.

List of Key Companies in Drug Delivery Systems Market

Companies with Diversified and Strong Product Portfolios to Hold Key Market Share

In terms of the competitive landscape, the scenario reflects a highly fragmented market with the entry of many small players in 2023.

BD, Baxter International Inc., Gerresheimer AG, and West Pharmaceutical Services Inc. are some of the prominent players operating in the market. BD is constantly focusing on introducing new products in the market.

• For instance, in September 2022, BD (Becton, Dickinson, and Company) launched a next-generation pre-fillable vaccine syringe, BD Effivax. The launch of this product will support the growth of the dedicated business of the company.

Other market players include Ypsomed, Medtronic, Nemera, and E3D Elcam Drug Delivery Devices. These companies are anticipated to increase their market shares during the forecast period by launching new and advanced products, and increasing their production capacities to meet the demand for drug delivery devices.

• For instance, in January 2023, Nemera inaugurated a new manufacturing facility in Poland to expand its manufacturing capacity of drug delivery solutions.

LIST OF KEY COMPANIES PROFILED:

• Gerresheimer AG (Germany)


• BD (Becton, Dickinson and Company) (U.S)


• Kindeva Drug Delivery (U.S.)


• Baxter (U.S.)


• West Pharmaceutical Services Inc. (U.S.)


• Ypsomed (Switzerland)


• Medtronic (Ireland)


• Nemara (France)


• E3D Elcam Drug Delivery Devices (Israel)

KEY INDUSTRY DEVELOPMENTS:

• January 2024:  Medtronic received CE mark approval for its MiniMed 780G system with Simplera Sync. MiniMed 780G, an automated insulin delivery system, offers meal detection technology and provides automatic adjustments and corrections to sugar levels every five minutes.


• February 2023:  Innovation Zed received the CE mark for its InsulCheck DOSE, a single unit add-on device for insulin pen injectors.


• September 2022: Corium, Inc., a biopharmaceutical company, launched ADLARITY, a donepezil transdermal system in the U.S. for treating patients suffering from mild to severe Alzheimer’s.


• August 2022: Baxter announced the U.S. FDA Clearance of the Novum IQ Syringe Infusion Pump with Dose IQ Safety Software. The Novum IQ Syringe infusion pumps precisely deliver small amounts of fluid at low rates, frequently in pediatric, neonatal or anesthesia care settings.


• June 2022: Gufic Biosciences Ltd launched a new drug delivery system: dual-chamber bags in India. These dual-chamber IV bags are made up of polypropylene with peel-able aluminum foil, allowing the storage of unstable drugs that need reconstitution just before their administration to the patient.


• March 2022: Vitaris, Inc., in partnership with Kindeva Drug Delivery L.P., received the U.S. FDA approval for Breyna, a drug-device inhalation aerosol combination for patients suffering from asthma and COPD.


• December 2021: Gerresheimer AG signed an agreement with American Biotech to develop a new pump to deliver a drug for the treatment of rare diseases via continuous parenteral administration.


• November 2021: AMW GmbH entered into a partnership with AdhexPharma to strengthen its transdermal drug delivery technologies. Through this partnership, the former focused on the development, marketing authorization, and licensing of its novel transdermal delivery systems.

REPORT COVERAGE

The global market research report delivers a detailed market analysis. It focuses on key aspects such as new product launches and technological advancements. Additionally, it includes an overview of all the segments and key industry developments such as mergers, partnerships, and acquisitions. Moreover, it covers regional analysis of different segments, key trends, and company profiles of top market players. Besides this, the report offers an overview of market trends, market opportunities, and the impact of the drug delivery systems on the stakeholders. The report encompasses qualitative and quantitative insights that contribute to the growth of the market.

Report Scope & Segmentation

ATTRIBUTE	DETAILS
Study Period	2019-2032
Base Year	2023
Estimated Year	2024
Forecast Period	2024-2032
Historical Period	2019-2022
Growth Rate	CAGR of 9.6% from 2024-2032
Unit	Value (USD billion)
Segmentation	By Type Inhalation Transdermal Injectable Others
By Device Type  Conventional Advanced
By Distribution Channel Hospital Pharmacies Retail Pharmacies Others
By Region North America (By Type, Device Type, Distribution Channel, and Country) U.S. Canada Europe (By Type, Device Type, Distribution Channel, and Country/Sub-region) U.K. Germany France Spain Italy Scandinavia Rest of Europe Asia Pacific (By Type, Device Type, Distribution Channel, and Country/Sub-region) China India Japan Australia Southeast Asia Rest of Asia Pacific Latin America (By Type, Device Type, Distribution Channel, and Country/Sub-region) Brazil Mexico Rest of Latin America Middle East & Africa (By Type, Device Type, Distribution Channel, and Country/Sub-region) GCC South Africa Rest of the Middle East & Africa